Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3761-3780 of 3,900 trials

Glioblastoma: Intraoperative Photodynamic Therapy with Pentalafen®

We are studying a new light-based treatment for adults with grade IV glioblastoma during surgery. The goal is to evaluate its safety and how well it works in reducing tumor response.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Hidradenitis Suppurativa: Sonelokimab Study

We are studying the long-term safety and effectiveness of sonelokimab for people with moderate to severe hidradenitis suppurativa. This research aims to improve symptoms and quality of life for participants.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

HIV-1 Prevention: MK-8527 Oral Medication

We are studying a new once-monthly pill, MK-8527, to see if it can effectively prevent HIV-1 infection compared to a daily treatment. The trial will also assess how safe and tolerable this new medication is for participants.

HIV-1>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

HIV Treatment: New Antibody Study

We are investigating whether adding a new antibody to current HIV medications helps reduce the viral reservoir in adults living with HIV. This study aims to improve treatment outcomes for those affected.

HIV Infection>2 yearsSafety phase (I)Infectious DiseasesInternal Medicine

Healthy Volunteers Needed: Itraconazole and BI 3031185 Study

We are testing how itraconazole affects the levels of BI 3031185 in the blood of healthy participants. This study aims to improve our understanding of drug interactions.

Healthy Volunteers≤3 monthsSafety phase (I)DermatologyInternal MedicineOphthalmologyOtolaryngologyPediatricsPsychiatry

Dengue Vaccine Qdenga: Antibody Response Study

We are examining how the Qdenga vaccine affects antibody levels for other flavivirus infections in Swedish travelers. This study aims to see if vaccination leads to higher antibody levels that could interfere with diagnostic tests.

Healthy Participants3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyHematologyInfectious Diseases

Healthy Volunteers Needed: BI 3000202 Interaction Study

We are testing how the new medication BI 3000202 affects the absorption of rosuvastatin and digoxin in healthy people. This research aims to improve our understanding of these drug interactions.

Healthy VolunteersSafety phase (I)Internal Medicine

Gene Therapy for Vision Loss: SPVN20 Study

We are testing a new gene therapy for people with no light perception due to end-stage rod cone dystrophy. The study aims to assess the safety and tolerability of a single injection in those who still have dormant cone photoreceptors.

Hereditary Retinal DystrophyEnd-stage Rod-Cone DystrophySafety phase (I)Ophthalmology

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Nasopharyngeal Carcinoma: Imaging Study with [68Ga]Ga-DOTA-TOC

We are exploring a new imaging method to assess tumors in patients with EBV-related nasopharyngeal carcinoma. This study aims to improve treatment choices by understanding how the tumor responds to therapy.

Nasopharyngeal Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Ulcerative Colitis: RO7837195 Treatment Study

We are testing a new medication, RO7837195, for people with moderately to severely active ulcerative colitis. The study aims to see if it can help induce remission and how safe it is compared to a placebo.

Ulcerative Colitis>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Cemiplimab and Imiquimod for High-Risk Basal Cell Carcinoma

We are studying a combination of cemiplimab, imiquimod, and laser therapy for patients with high-risk cutaneous basal cell carcinoma. The goal is to evaluate safety and how well this treatment works before surgery.

Skin Cancer (Basal Cell Carcinoma)>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyOncology

Ulcerative Colitis: SAR441566 Study

We are investigating the effects of SAR441566 in adults with moderate-to-severe ulcerative colitis. The study aims to see if different doses can help achieve remission and improve overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Primary Aldosteronism: Baxdrostat Study

We are investigating how safe and effective baxdrostat is for adults with primary aldosteronism. The goal is to see if it can improve blood pressure and other health measures compared to a placebo.

Primary Hyperaldosteronism1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Advanced Colorectal Cancer: OMTX705 Combination Therapy

We are studying a new drug, OMTX705, combined with regorafenib and tislelizumab for patients with advanced colorectal cancer. The goal is to evaluate its safety and effectiveness in those who have not responded to previous treatments.

Metastatic Colorectal Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Fluid Management in Critically Ill Adults: CRUSADERS Trial

We are studying whether reducing sodium and chloride in fluids helps critically ill adults have better health outcomes. This includes looking at effects on organ support needs and overall survival.

Healthy Participants>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrology